3Rahman A, Dhar DK, Yamagnchi E, et al. Coexpression of inducible nitric oxide synthase and COX - 2 in hepatocetlular carcinoma and surrounding liver, possible involvement of COX - 2 in the angiogenesis of hepatitis C virus positive case[J]. Clin Can Res,2001,7(5) : 1325.
4Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors[J]. Breast Cancer Res Treat, 1995,36: 169.
5Lever A, Hole D,Gillis C,et al. Do inhibitors of angiotensin - I converting enzyme protect against risk of cancer? [J]. Lancet, 1998,352: 179 - 184.
6Koh WP, Yuan JM, Sun CL, et al. Angiotensin I - converting enzyme (ACE) gene polymorphism and breast cancer risk among chinese women in singapore[J]. Cancer Research,2003, 63 : 573 - 578.
7Angela M, Ladd GZ, Vasquez AA, et al. Angiotensin- converting enzyme gene insertion/deletion polymorphism and breast cancer risk[J]. Cancer Epidemiology Biomarkers & Prevention, 2005,14:2143 - 2146.
8Rocken C, Lendeckel U,Dierkes J, et al. The number of lymp - h node metastases in gastric cancer correlates with the angiotensin I - converting enzyme gene insertion/deletion poly- morphism[J]. Clinical Cancer Research,2005,11:2526 - 2530.
9Chen L, Re RN, Prakash O, et al. Angiotensin - converting enzyme inhibition reduces neuroblastoma cell growth rate [J]. Proc Soc Exp Biol Med,1991,196:280-283.
10Reddy MK,Baskaran K, Molteni A, et al. Inhibitors of angiotensin - converting enzyme modulate mitosis and gene expression in pa - ncreatic cancer cells[J]. Proceedings of the Society for Experimental Biology and Medicine, 1995,210:221 - 226.
二级参考文献3
1吴权威.中文Excel一册通[M].大连:大连理工大学出版社,2000.273-275.
2倪宗瓒.卫生统计学（第4版）[M].北京:人民卫生出版社,2000..
3Brown ML.Present knowledge in nutrition.Sixth edition.Washington:International Life Sciences Institute Nutrition Foundation,1990,399-392.
5Yamamoto S,Konishi I, Mandai M, e t al. Expression of vascu- lar endothelial growth factor(VEGF)in epithelial ovarian neo- plasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels[J].Br J Cancer, 1997, 76 (9): 1221 -1227.
6Fujimoto J ,Sakaguchi H, Hirose R, et al. Biologic implications of the expression of vascular endothelial growth factor sub- types in ovarian careinoma[J]. Cancer, 1998, 83 (12) : 2528- 2533.
7Shen GH, Ghazizadeh M, Kawanami O, et al. Prognostic signif- icance of vascular endothelial growth factor expression in hu- man ovarian carcinoma[J].Br J Cancer, 2000,83 ( 2 ) : 196-203.
8Koh WP, Yuan J M, Sun CL, et al. Angiotenensin I-converting enzyme(ACE) gene polymorphismad breast cancer risk among Chinese women in Singapore [J]. Cancer Res, 2003, 63 (3): 573-578.
9Won SM, Park YH, Kim HJ, et al. Catechins inhibit angioten- sin II induced vascular smooth muscle cell proliferation via mi- togen-activated protein kinase pathway[J]. Exp Mol Med, 2006,38 (5) : 525-534.
10Suganuma T, Ino K,Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma ceils and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination[J]. Clin Cancer Res,2005,11 (7) : 2 686 -2 694.
